FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

https://ir.intelliatx.com/news-releases/news-release-details/fda-accepts-investigational-new-drug-application-crisprcas9
JOIN OUR MAILING LIST

 

 
 
 
 

IPIRA is committed to meeting the needs of people with disabilities in a timely manner by preventing and removing barriers to accessibility. We also adhere to the UC Berkeley policy on nondiscrimination, and protect the privacy of confidential information.